ERBB2 and breast carcinoma: And according to National Comprehensive Cancer Network (NCCN) guidelines, breast carcinoma patients with triple negative immunohistochemical markers; Estrogen, Progesterone and HER2/ Neu, with age equal or less than 60 should be screened for BRCA mutations/variants.